NAD+ Treatment Guide

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, involved in energy metabolism and DNA repair. This page explains what it is, what the evidence does and does not show, and how clinician-supervised programs through ElliotMeds work. It is educational and not medical advice.

Last updated: July 17, 2026

What Is NAD+?

NAD+ stands for nicotinamide adenine dinucleotide. It is a coenzyme — a helper molecule that enzymes need in order to work — and it is present in every cell in the body. NAD+ is not a peptide. Peptides are short chains of amino acids. NAD+ is a dinucleotide, built from two nucleotides joined together, and belongs to a different chemical family entirely. The body makes its own NAD+, primarily from vitamin B3 in the diet, and recycles it continuously. Tissue NAD+ levels have been observed to decline with age in laboratory studies, which is the observation most interest in NAD+ is built on.

How It Works

NAD+ has two broad roles in cells. The first is metabolic. NAD+ cycles between an oxidized form (NAD+) and a reduced form (NADH), shuttling electrons through the reactions that produce ATP, the cell's energy currency. Without NAD+, those reactions stop. The second is regulatory. NAD+ is consumed as a substrate by enzymes including sirtuins and PARPs, which are involved in DNA repair and gene regulation. Because these enzymes use NAD+ up rather than recycling it, their activity depends on how much is available. What is not established is whether raising NAD+ by injection changes any of this in a way that produces a clinical benefit in humans. That is the gap between the biochemistry, which is well described, and the therapeutic claims, which are not.

What It’s Studied For

Research on NAD+ and its precursors has looked at aging, metabolic function, neurodegenerative disease, and substance-use disorders. Most of this work is preclinical — cell cultures and animal models — or consists of small, short human trials, often of oral precursors such as nicotinamide riboside or nicotinamide mononucleotide rather than injected NAD+ itself. There are no large, randomized, controlled trials establishing that injectable NAD+ improves any clinical outcome, and no NAD+ drug product has been approved by the FDA for any indication.

Regulatory Status

No NAD+ drug product is FDA-approved for any indication. NAD+ appears in Category 1 of the FDA's list of bulk drug substances nominated for use in compounding under section 503A — substances the agency is still evaluating. Under the FDA's interim policy, FDA does not intend to take action against compounding with Category 1 substances, subject to the conditions in that policy. Compounded NAD+ has not been evaluated by the FDA for safety, effectiveness, or quality before marketing. In 2019 the FDA proposed a rule that would not include NAD on the final 503A bulks list; that rule has not been finalized. Availability is subject to this status and may change.

How It May Be Used in a Clinician-Supervised Program

Through ElliotMeds, NAD+ is available only after a licensed clinician reviews your medical intake and determines that a program is appropriate. The clinician decides the medication, the strength, and whether to prescribe at all — and may decline. If prescribed, NAD+ is compounded and dispensed by a licensed U.S. pharmacy. Compounded medications are not FDA-approved, and the FDA does not evaluate them for safety, effectiveness, or quality before marketing. Nothing on this page guarantees prescribing, approval, or any specific outcome.

What to Expect

Use is provider-directed only. No energy, cognitive, longevity, or disease outcome is promised, and no timeline is implied. Effects are individual and are not established for these purposes.

Preferred Starting Options / Dosing Notes

Many patients begin with a lower starting option so a licensed clinician can evaluate tolerance, medical history, goals, and safety factors before any adjustments are considered. The starting option shown below is informational and reflects available program data, not self-directed dosing instructions. Final medication, dose, frequency, and treatment plan are determined by a licensed clinician.

Safety Considerations

• No NAD+ product is FDA-approved for any medical use. Compounded NAD+ has not been evaluated by the FDA for safety, effectiveness, or quality before marketing.
• Reported effects of NAD+ injection include nausea, cramping, flushing, headache, fatigue, and chest tightness. Injection-site tenderness, swelling, and bruising are common.
• These effects are strongly rate-dependent — administering NAD+ too quickly is the usual reason people feel unwell during it.
• Because there are no large controlled trials, the long-term safety of repeated NAD+ administration is not established.
• Tell your clinician about all medications, supplements, and medical conditions, including pregnancy or breastfeeding, before starting any NAD+ program.
• NAD+ is not a treatment for any disease. If you have symptoms that concern you, see a licensed clinician for evaluation rather than self-treating.

Who Is Not a Candidate

A clinician reviews your goals, medical history, cardiovascular status, liver and kidney function, allergies, pregnancy or breastfeeding status, and current medications and supplements before considering NAD+. NAD+ is not appropriate for everyone, and a clinician may decline.

Frequently Asked Questions

References

• Peer-reviewed literature on nicotinamide adenine dinucleotide (PubMed / MedlinePlus)
• FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (Category 1)